JP2017504571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504571A5 JP2017504571A5 JP2016534731A JP2016534731A JP2017504571A5 JP 2017504571 A5 JP2017504571 A5 JP 2017504571A5 JP 2016534731 A JP2016534731 A JP 2016534731A JP 2016534731 A JP2016534731 A JP 2016534731A JP 2017504571 A5 JP2017504571 A5 JP 2017504571A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- group
- pharmaceutically acceptable
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 107
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 12
- OZAYOHJGXLWETR-QGZVFWFLSA-N 4-[(3R)-1-[(2-chloro-4-fluorophenyl)methyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide Chemical compound ClC1=C(CN2C[C@@H](CCC2)OC2=CC(=C(C(=O)NS(=O)(=O)C)C=C2C2CC2)F)C=CC(=C1)F OZAYOHJGXLWETR-QGZVFWFLSA-N 0.000 claims 3
- PRCIGHMFXRYAIG-INIZCTEOSA-N 5-cyclopropyl-N-cyclopropylsulfonyl-4-[[1-[(1S)-1-(3,5-dichlorophenyl)ethyl]piperidin-4-yl]methoxy]-2-fluorobenzamide Chemical compound C1(CC1)C=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)OCC1CCN(CC1)[C@@H](C)C1=CC(=CC(=C1)Cl)Cl PRCIGHMFXRYAIG-INIZCTEOSA-N 0.000 claims 3
- KRNHAUPCKRIYSK-LJQANCHMSA-N N-(azetidin-1-ylsulfonyl)-4-[(3R)-1-[(2-chloro-4-fluorophenyl)methyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluorobenzamide Chemical compound FC1=CC=C(CN2CCC[C@H](C2)OC2=CC(F)=C(C=C2C2CC2)C(=O)NS(=O)(=O)N2CCC2)C(Cl)=C1 KRNHAUPCKRIYSK-LJQANCHMSA-N 0.000 claims 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- CIXVIWMKNATLIZ-CRAIPNDOSA-N 4-[(3R)-1-[(1R)-1-(5-chloro-6-cyclopropylpyridin-2-yl)ethyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide Chemical compound ClC=1C=CC(=NC=1C1CC1)[C@@H](C)N1C[C@@H](CCC1)OC1=CC(=C(C(=O)NS(=O)(=O)C)C=C1C1CC1)F CIXVIWMKNATLIZ-CRAIPNDOSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 75
- 125000000217 alkyl group Chemical group 0.000 description 56
- -1 C1-8Alkyl Chemical group 0.000 description 52
- 125000003545 alkoxy group Chemical group 0.000 description 52
- 229910052739 hydrogen Inorganic materials 0.000 description 51
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 44
- 208000002193 Pain Diseases 0.000 description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 38
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 description 35
- 125000004419 alkynylene group Chemical group 0.000 description 30
- 239000001257 hydrogen Substances 0.000 description 30
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 30
- 125000000623 heterocyclic group Chemical group 0.000 description 25
- 125000001188 haloalkyl group Chemical group 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 125000004663 dialkyl amino group Chemical group 0.000 description 15
- 125000004450 alkenylene group Chemical group 0.000 description 14
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000004474 heteroalkylene group Chemical group 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 206010065390 Inflammatory pain Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 3
- 206010020844 Hyperthermia malignant Diseases 0.000 description 3
- 208000007914 Labor Pain Diseases 0.000 description 3
- 208000035945 Labour pain Diseases 0.000 description 3
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 3
- 208000026709 Liddle syndrome Diseases 0.000 description 3
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010061533 Myotonia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 3
- 206010029279 Neurogenic bladder Diseases 0.000 description 3
- 208000012075 Paroxysmal dystonia Diseases 0.000 description 3
- 208000010886 Peripheral nerve injury Diseases 0.000 description 3
- 208000004983 Phantom Limb Diseases 0.000 description 3
- 206010056238 Phantom pain Diseases 0.000 description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 206010037113 Pseudoaldosteronism Diseases 0.000 description 3
- 208000005793 Restless legs syndrome Diseases 0.000 description 3
- 206010039020 Rhabdomyolysis Diseases 0.000 description 3
- 206010040744 Sinus headache Diseases 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 206010043269 Tension headache Diseases 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000010118 dystonia Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 201000007004 malignant hyperthermia Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000036473 myasthenia Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 150000001539 azetidines Chemical class 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/001452 | 2013-11-27 | ||
| CN2013001452 | 2013-11-27 | ||
| CN2013088062 | 2013-11-28 | ||
| CNPCT/CN2013/088062 | 2013-11-28 | ||
| CN2014090171 | 2014-11-03 | ||
| CNPCT/CN2014/090171 | 2014-11-03 | ||
| PCT/CN2014/092269 WO2015078374A1 (en) | 2013-11-27 | 2014-11-26 | Substituted benzamides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146542A Division JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504571A JP2017504571A (ja) | 2017-02-09 |
| JP2017504571A5 true JP2017504571A5 (enExample) | 2017-12-28 |
| JP6383418B2 JP6383418B2 (ja) | 2018-08-29 |
Family
ID=53198372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534731A Expired - Fee Related JP6383418B2 (ja) | 2013-11-27 | 2014-11-26 | 置換ベンズアミド及びその使用方法 |
| JP2018146542A Pending JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146542A Pending JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9546164B2 (enExample) |
| EP (2) | EP3450428A1 (enExample) |
| JP (2) | JP6383418B2 (enExample) |
| KR (1) | KR20160090846A (enExample) |
| CN (1) | CN105793238B (enExample) |
| AU (1) | AU2014356967A1 (enExample) |
| CA (1) | CA2931732A1 (enExample) |
| CL (1) | CL2016001287A1 (enExample) |
| CR (1) | CR20160296A (enExample) |
| EA (1) | EA201691085A1 (enExample) |
| IL (1) | IL245844A0 (enExample) |
| MX (1) | MX2016006936A (enExample) |
| PE (1) | PE20161247A1 (enExample) |
| PH (1) | PH12016501007A1 (enExample) |
| TW (1) | TWI560180B (enExample) |
| WO (1) | WO2015078374A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| BR112014029161A2 (pt) * | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2016124140A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| WO2016191312A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| MX382092B (es) * | 2015-11-13 | 2025-03-04 | Oppilan Pharma Ltd | Compuestos heterocíclicos para el tratamiento de enfermedades. |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| EP3383389B1 (en) | 2015-11-30 | 2021-04-28 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
| TW201726637A (zh) | 2015-12-18 | 2017-08-01 | 默沙東藥廠 | 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物 |
| AU2017215697A1 (en) * | 2016-02-03 | 2018-07-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| KR102366077B1 (ko) * | 2016-05-20 | 2022-02-21 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| KR20190086772A (ko) | 2016-12-09 | 2019-07-23 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN110300745B (zh) * | 2017-07-24 | 2023-03-31 | 上海海雁医药科技有限公司 | 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| WO2019045035A1 (en) | 2017-08-31 | 2019-03-07 | Raqualia Pharma Inc. | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS |
| CN109574927A (zh) * | 2017-09-29 | 2019-04-05 | 浙江海正药业股份有限公司 | N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途 |
| ES3064093T3 (en) | 2017-10-20 | 2026-04-22 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| WO2020248123A1 (en) * | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| JPWO2021132577A1 (enExample) * | 2019-12-27 | 2021-07-01 | ||
| CN111303120A (zh) * | 2020-03-14 | 2020-06-19 | 江巨东 | 一种盐酸法舒地尔的制备方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| WO2023023532A2 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors |
| CN118019735A (zh) | 2021-08-18 | 2024-05-10 | 坎莫森特里克斯公司 | 作为ccr6抑制剂的芳基磺酰基化合物 |
| EP4174077A1 (en) * | 2021-10-27 | 2023-05-03 | Merck Patent GmbH | Electronic switching device |
| CN119836422A (zh) | 2022-07-06 | 2025-04-15 | 奥比兰制药有限公司 | S1p受体调节剂的结晶形式 |
| CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
| GR71915B (enExample) * | 1979-11-27 | 1983-08-16 | Pfizer | |
| GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| DK24089D0 (da) | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| DE69332691T2 (de) | 1992-11-23 | 2003-12-18 | Aventis Pharmaceuticals Inc., Cincinnati | Substituierte 3-(aminoalkylamino)-1,2-benzisoxazole und verwandte verbindungen |
| US5573653A (en) | 1994-07-11 | 1996-11-12 | Sandoz Ltd. | Electrochemical process for thiocyanating aminobenzene compounds |
| AU688102B2 (en) | 1994-08-30 | 1998-03-05 | Sankyo Company Limited | Isoxazoles |
| US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| KR100789567B1 (ko) | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
| DE10201550A1 (de) | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
| US7332486B2 (en) | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| EA200501462A1 (ru) | 2003-04-15 | 2006-04-28 | Пфайзер Инк. | Альфа-замещенные карбоновые кислоты в качестве модуляторов ppar |
| ZA200601942B (en) | 2003-08-08 | 2007-05-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| TW200524888A (en) | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
| WO2005032488A2 (en) | 2003-10-03 | 2005-04-14 | Portola Pharmaceuticals, Inc. | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| US7081539B2 (en) | 2004-03-25 | 2006-07-25 | Dainippon Sumitomo Pharma Co., Ltd. | One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide |
| AU2005267883A1 (en) | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
| ES2343640T3 (es) | 2004-08-12 | 2010-08-05 | Amgen Inc. | Bisaril-sulfonamidas. |
| NZ554211A (en) | 2004-09-29 | 2010-10-29 | Portola Pharm Inc | Substituted 2H-1,3-Benzoxazin-4(3H)-ones |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
| CN101287702A (zh) | 2005-10-19 | 2008-10-15 | 弗·哈夫曼-拉罗切有限公司 | N-苯基苯乙酰胺非核苷逆转录酶抑制剂 |
| WO2007062078A2 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| ATE542818T1 (de) | 2006-10-11 | 2012-02-15 | Amgen Inc | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung |
| JP2010516812A (ja) | 2007-01-30 | 2010-05-20 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 有糸分裂キナーゼの調節剤 |
| JP2010518026A (ja) | 2007-02-05 | 2010-05-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 |
| ATE461177T1 (de) | 2007-03-23 | 2010-04-15 | Icagen Inc | Ionenkanal-hemmer |
| NZ581309A (en) * | 2007-05-25 | 2012-02-24 | Vertex Pharma | Ion channel modulators and methods of use |
| EP2154130A4 (en) | 2007-06-07 | 2011-09-07 | Astellas Pharma Inc | pyridone |
| US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| TW200911766A (en) | 2007-07-13 | 2009-03-16 | Astrazeneca Ab | New compounds |
| JPWO2009022731A1 (ja) | 2007-08-10 | 2010-11-18 | 日本ケミファ株式会社 | Ｐ２ｘ４受容体拮抗剤 |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN101981003B (zh) * | 2008-02-29 | 2014-07-02 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
| EP2305641A4 (en) | 2008-06-23 | 2012-08-22 | Astellas Pharma Inc | SULPHONAMIDE COMPOUND OR SALT THEREOF |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
| US8809380B2 (en) | 2009-08-04 | 2014-08-19 | Raqualia Pharma Inc. | Picolinamide derivatives as TTX-S blockers |
| RU2609021C2 (ru) | 2009-09-25 | 2017-01-30 | Астеллас Фарма Инк. | Замещенные соединения амида |
| WO2011059042A1 (ja) | 2009-11-12 | 2011-05-19 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2011063001A1 (en) | 2009-11-18 | 2011-05-26 | Concert Pharmaceuticals, Inc. | Niacin prodrugs and deuterated versions thereof |
| TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| HUE029012T2 (en) | 2010-02-12 | 2017-02-28 | Nivalis Therapeutics Inc | New S-nitrosoglutathion reductase inhibitors |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| EP2588186A1 (en) | 2010-06-30 | 2013-05-08 | Cardiac Pacemakers, Inc. | Lead having coil electrode with preferential bending region |
| US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| JP2013531030A (ja) * | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| CA2804716A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| ES2526541T3 (es) * | 2010-07-12 | 2015-01-13 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
| JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
| CA2812081A1 (en) | 2010-09-13 | 2012-03-22 | Novartis Ag | Triazine-oxadiazoles |
| WO2012039657A1 (en) | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
| JP2014500303A (ja) | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としての置換ピリジン |
| WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| BR112013019211A2 (pt) | 2011-02-02 | 2021-07-06 | Vertex Pharma | amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| JP2014528486A (ja) | 2011-10-13 | 2014-10-27 | ケース ウエスタン リザーブ ユニバーシティ | Ｒｘｒアゴニスト化合物および方法 |
| MX2014005068A (es) | 2011-10-28 | 2014-07-30 | Merck Sharp & Dohme | Compuestos de benzoxazolinona con actividad selectiva en canales de sodio activados por voltaje. |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| ES2593533T3 (es) * | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
| WO2013102826A1 (en) * | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
| JP2015083542A (ja) * | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2013146969A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規二置換シクロヘキサン誘導体 |
| BR112014029161A2 (pt) * | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| BR112015000187A2 (pt) * | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| EP2876105A4 (en) * | 2012-07-19 | 2016-01-13 | Sumitomo Dainippon Pharma Co Ltd | 1- (CYCLOALKYL-CARBONYL) PROLIN DERIVATIVE |
| US9624208B2 (en) | 2012-10-26 | 2017-04-18 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| BR112015022096A8 (pt) | 2013-03-15 | 2019-11-26 | Chromocell Corp | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
-
2014
- 2014-11-26 CR CR20160296A patent/CR20160296A/es unknown
- 2014-11-26 MX MX2016006936A patent/MX2016006936A/es unknown
- 2014-11-26 EP EP18197734.9A patent/EP3450428A1/en not_active Withdrawn
- 2014-11-26 CN CN201480064734.4A patent/CN105793238B/zh not_active Expired - Fee Related
- 2014-11-26 CA CA2931732A patent/CA2931732A1/en not_active Abandoned
- 2014-11-26 EP EP14865855.2A patent/EP3074377B1/en active Active
- 2014-11-26 WO PCT/CN2014/092269 patent/WO2015078374A1/en not_active Ceased
- 2014-11-26 EA EA201691085A patent/EA201691085A1/ru unknown
- 2014-11-26 KR KR1020167016643A patent/KR20160090846A/ko not_active Withdrawn
- 2014-11-26 PE PE2016000696A patent/PE20161247A1/es not_active Application Discontinuation
- 2014-11-26 AU AU2014356967A patent/AU2014356967A1/en not_active Abandoned
- 2014-11-26 JP JP2016534731A patent/JP6383418B2/ja not_active Expired - Fee Related
- 2014-11-27 TW TW103141262A patent/TWI560180B/zh not_active IP Right Cessation
-
2015
- 2015-01-22 US US14/603,273 patent/US9546164B2/en not_active Expired - Fee Related
-
2016
- 2016-05-25 IL IL245844A patent/IL245844A0/en unknown
- 2016-05-26 CL CL2016001287A patent/CL2016001287A1/es unknown
- 2016-05-27 PH PH12016501007A patent/PH12016501007A1/en unknown
- 2016-09-23 US US15/275,131 patent/US9694002B2/en not_active Expired - Fee Related
-
2018
- 2018-08-03 JP JP2018146542A patent/JP2018188466A/ja active Pending
-
2019
- 2019-04-22 US US16/390,957 patent/US20200108054A1/en not_active Abandoned
- 2019-11-07 US US16/677,487 patent/US20210093618A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013370300B2 (en) | Novel antiviral agents against HBV infection | |
| JP2015523369A5 (enExample) | ||
| CA3105748A1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| RU2014121984A (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| TW201716397A (zh) | 作為組蛋白去乙醯酶6抑制劑之 二唑胺衍生物及含彼之醫藥組合物 | |
| CA2570999A1 (en) | Compounds, compositions and methods | |
| AU2016299486A1 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2014532640A5 (enExample) | ||
| RS60569B1 (sr) | Jedinjenja karbamata i postupci njihovog pravljenja i upotrebe | |
| CN107001372A (zh) | 取代的氨基嘌呤化合物、其组合物及其治疗方法 | |
| CA3011465A1 (en) | Pyridazine derivatives as eaat2 activators | |
| EA007297B1 (ru) | Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина | |
| HUE032075T2 (en) | 3-(2-aryl-cycloalkenylmethyl)-oxazolidin-2-one derivatives as cholesterol ester transfer protein (cetp) inhibitors | |
| JP2017516819A (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体 | |
| BR112018069930B1 (pt) | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica | |
| RU2018124591A (ru) | Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение | |
| JP3058746B2 (ja) | 置換ｎ−フェニルピペリジン | |
| RU2013130019A (ru) | Новые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| US20210040034A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| CN119110795A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| JP2024545552A (ja) | Ｒｉｐｋ１阻害剤として縮合したヘテロ環 | |
| RU2565766C1 (ru) | 4-(3,4-дибромтиофенкарбонил)-2,6,8,12-тетраацетил-2,4,6,8,10,12-гексаазатетрацикло[5,5,0,03,11,05,9]додекан в качестве анальгетического средства и способ его получения | |
| CN111936488B (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| CN113045487A (zh) | 一种选择性钠通道调节剂及其制备和应用 | |
| WO2024255859A1 (zh) | 作为at2r拮抗剂的杂环化合物及其用途 |